DaVita Price Target Raised to $150.00/Share From $139.00 by TD Cowen
TD Cowen Maintains Hold on DaVita, Raises Price Target to $150
DaVita Analyst Ratings
These 4 Measures Indicate That DaVita (NYSE:DVA) Is Using Debt Reasonably Well
Express News | DaVita Inc : TD Cowen Raises Target Price to $150 From $139
TD Cowen Initiates DaVita(DVA.US) With Hold Rating, Announces Target Price $150
Balanced Outlook: Hold Rating on DaVita Amid Valuation and Regulatory Uncertainties
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
What to Expect From DaVita's Q2 2024 Earnings Report
Express News | DaVita Shares Down 1.4% in Volume Spike After Reaching Agreement With Justice Department to Resolve Kickback Allegations
Express News | U.S. Justice Department Says DaVita to Pay Over $34 Million to Resolve Allegations of Illegal Kickbacks
Express News | DaVita To Pay Over $34M To Settle Illegal Kickback Allegations
DaVita Inc. Schedules 2nd Quarter 2024 Investor Conference Call
DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts
DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?
Renal Denervation Devices Market Expected to Reach USD 387 Million by 2032 With a Remarkable 37.2% CAGR, According to Straits Research
Express News | DaVita and Fresenius Shares Are Trading Lower Following a Report Suggesting the FTC Is Investigating the Companies
Express News | DaVita Shares Fall 2.6% After Report That US FTC Is Investigating Co Over Allegations of Illegally Thwarting Smaller Competitors
TD Cowen Reaffirms Their Hold Rating on DaVita (DVA)
Fresenius Medical Care, DaVita Brace for Competition, Shift to Home Dialysis -- Market Talk